NCT03282643

Rivaroxaban Versus Low-molecular-weight Heparin for Preventing Thrombosis in Cancer Patients

Rivaroxaban Versus Low-molecular-weight Heparin in Preventing Thrombosis Among Cancer Patients After Femoral Venepuncture

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 74 (actual)
• Sponsor: Capital Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The study is designed to compare the efficacy and safety of oral rivaroxaban and subcutaneous low-molecular-weight heparin in preventing femoral venepuncture associated thrombosis among cancer patients.

Conditions

• Neoplasms

Interventions

Type	Name	Description
DRUG	Rivaroxaban 10 MG	Rivaroxaban pill 10mg qd, day1 and day2 after femoral venepuncture
DRUG	Rivaroxaban 20 MG	Rivaroxaban pill 10mg bid, day1 and day2 after femoral venepuncture
DRUG	Low-molecular-weight heparin	0.4 ml once daily, before femoral venepuncture(day1) and the following day (day 2)

Timeline

• Start date: 2016-02-16
• Primary completion: 2018-06-30
• Completion: 2019-04-01
• First posted: 2017-09-14
• Last updated: 2019-04-16

Locations

1 site across 1 country: China